Findings

What do systematic reviews say?

2,261 questions · 2,280 findings · 114 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 856 · 37.5%GRADE not reported 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%

Probiotics vs placebo

HRQoL (PedsQLTM 4.0 SF 15 (Scale from: 0 to 100)) · children and adults with CF

1 finding from 1 review

Probiotics for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
Low

Intervention vs usual care

Change in quality of life · postural abnormalities in people with cystic fibrosis

1 finding from 1 review

Physical therapies for postural abnormalities in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 50 participants
Very low

Intervention vs usual care

Change in pain (mm) · postural abnormalities in people with cystic fibrosis

1 finding from 1 review

Physical therapies for postural abnormalities in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 50 participants
Very low

Intervention vs usual care

Change in trunk deformity (cm) · postural abnormalities in people with cystic fibrosis

1 finding from 1 review

Physical therapies for postural abnormalities in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 50 participants
Very low

Intervention vs usual care

Lung function: FEV1 mL (change from baseline) · postural abnormalities in people with cystic fibrosis

1 finding from 1 review

Physical therapies for postural abnormalities in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 50 participants
Very low

Intervention vs usual care

Change in FVC · postural abnormalities in people with cystic fibrosis

1 finding from 1 review

Physical therapies for postural abnormalities in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 50 participants
Very low

Intervention vs usual care

Change in ERV (L) · postural abnormalities in people with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Physical therapies for postural abnormalities in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention vs usual care

Change in TLC (L) · postural abnormalities in people with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Physical therapies for postural abnormalities in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Number of minor postoperative bleeding episodes · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
This outcome was not reported in either of the trials.
0 studies
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Outcome not reported · People with Von Willebrand disease undergoing minor oral surgery or dental extractions

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
No randomised or quasi-randomised controlled trials in people with Von Willebrand disease met the inclusion criteria; no eligible VWD trials were identified.
0 studies
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Major bleeding, requiring transfusion of packed red blood cells · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Only reported in the Walsh (EACA) trial: in none of the 31 included participants was blood transfusion required.
1 study · 31 participants
GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Change in haemoglobin level from baseline · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Mean fall in haemoglobin. Forbes (TXA): 1.4 g/100 mL (placebo) vs 0.3 g/100 mL (TXA). Walsh (EACA): 6.3% (placebo, both centres) vs 3.9% and 3.7% (EACA, centres 1 and 2); differences not significant. Reported in…
2 studies · 59 participants
GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Bleeding duration · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
This outcome was not reported in either of the trials.
0 studies
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Need for and dose of clotting factor concentrates · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Reported in both trials in different ways. Forbes (TXA): mean units of replacement therapy per root extracted 617 IU (range 0 to 15,800) in 11 placebo participants versus 30 IU and 65 IU per root in 2 TXA participants…
2 studies · 59 participants
GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Any postoperative complication except bleeding (e.g. wound infection) · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
This outcome was not reported in either of the trials.
0 studies
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Number of postoperative bleeding episodes requiring intervention · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… probably leads to lower number of postoperative bleeding episodes requiring intervention compared with placebo, no intervention or usual care (with or without placebo) (moderate certainty).

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Up to 10 days postoperative
RD -0.57 [-0.76, -0.37]
2 studies · 59 participants
Moderate

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Amount of postoperative blood loss (mL) · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Only reported in the Forbes (TXA) trial: over five-day follow-up, mean blood loss per participant 84.1 mL (range 4 to 323) in the placebo group (n=14) versus 61.2 mL (range 1 to 749) in the TXA group (n=14), P = 0.02.
1 study · 28 participants
GRADE not reported

NSAIDs vs placebo

Annual rate of change in % predicted FEV1 All participants · adults and children with cystic fibrosis

1 finding from 1 review

Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 226 participants
Moderate

NSAIDs vs placebo

Annual rate of change in % predicted FEV1 Subgroup: under 13 years of age · adults and children with cystic fibrosis

1 finding from 1 review

Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 147 participants
Moderate

NSAIDs vs placebo

Annual rate of change in % predicted FEV1 Subgroup: over 13 years of age · adults and children with cystic fibrosis

1 finding from 1 review

Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 79 participants
Moderate